148 related articles for article (PubMed ID: 9857091)
1. Repaglinide and related hypoglycemic benzoic acid derivatives.
Grell W; Hurnaus R; Griss G; Sauter R; Rupprecht E; Mark M; Luger P; Nar H; Wittneben H; Müller P
J Med Chem; 1998 Dec; 41(26):5219-46. PubMed ID: 9857091
[TBL] [Abstract][Full Text] [Related]
2. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels.
Stephan D; Winkler M; Kühner P; Russ U; Quast U
Diabetologia; 2006 Sep; 49(9):2039-48. PubMed ID: 16865362
[TBL] [Abstract][Full Text] [Related]
3. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.
Winkler M; Stephan D; Bieger S; Kühner P; Wolff F; Quast U
J Pharmacol Exp Ther; 2007 Aug; 322(2):701-8. PubMed ID: 17495126
[TBL] [Abstract][Full Text] [Related]
4. Hypoglycaemic effects of the novel antidiabetic agent repaglinide in rats and dogs.
Mark M; Grell W
Br J Pharmacol; 1997 Aug; 121(8):1597-604. PubMed ID: 9283692
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
[TBL] [Abstract][Full Text] [Related]
6. [Structures and mechanisms for non SU insulin secretagogues].
Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():362-70. PubMed ID: 12387019
[No Abstract] [Full Text] [Related]
7. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride.
Kramer W; Müller G; Girbig F; Gutjahr U; Kowalewski S; Hartz D; Summ HD
Biochim Biophys Acta; 1994 May; 1191(2):278-90. PubMed ID: 8172913
[TBL] [Abstract][Full Text] [Related]
8. Conformational analysis of non-sulfonylurea hypoglycemic agents of the meglitinide family.
Lins L; Brasseur R; Malaisse WJ
Biochem Pharmacol; 1995 Nov; 50(11):1879-84. PubMed ID: 8615868
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-benzoic acid ([11C]methoxy-repaglinide): a potential beta-cell imaging agent.
Wängler B; Beck C; Shiue CY; Schneider S; Schwanstecher C; Schwanstecher M; Feilen PJ; Alavi A; Rösch F; Schirrmacher R
Bioorg Med Chem Lett; 2004 Oct; 14(20):5205-9. PubMed ID: 15380228
[TBL] [Abstract][Full Text] [Related]
10. A novel simple method for the investigation of drug binding to the K(ATP) channel sulfonylurea receptor.
Mikhailova EA; Ashcroft SJ; Mikhailov MV
Anal Biochem; 2002 Aug; 307(2):383-5. PubMed ID: 12202259
[No Abstract] [Full Text] [Related]
11. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.
Fuhlendorff J; Rorsman P; Kofod H; Brand CL; Rolin B; MacKay P; Shymko R; Carr RD
Diabetes; 1998 Mar; 47(3):345-51. PubMed ID: 9519738
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacology of glimepiride].
Satoh Y
Nihon Rinsho; 1997 Nov; 55 Suppl():147-51. PubMed ID: 9434459
[No Abstract] [Full Text] [Related]
13. Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.
Hansen AM; Hansen JB; Carr RD; Ashcroft FM; Wahl P
Br J Pharmacol; 2005 Feb; 144(4):551-7. PubMed ID: 15678092
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells.
Kramer W; Müller G; Geisen K
Horm Metab Res; 1996 Sep; 28(9):464-8. PubMed ID: 8911984
[TBL] [Abstract][Full Text] [Related]
15. Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats.
Ladrière L; Malaisse-Lagae F; Fuhlendorff J; Malaisse WJ
Eur J Pharmacol; 1997 Sep; 335(2-3):227-34. PubMed ID: 9369378
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbamoyl]-methyl)-benzoic acid ([18F]repaglinide): a promising radioligand for quantification of pancreatic beta-cell mass with positron emission tomography (PET).
Wängler B; Schneider S; Thews O; Schirrmacher E; Comagic S; Feilen P; Schwanstecher C; Schwanstecher M; Shiue CY; Alavi A; Höhnemann S; Piel M; Rösch F; Schirrmacher R
Nucl Med Biol; 2004 Jul; 31(5):639-47. PubMed ID: 15219283
[TBL] [Abstract][Full Text] [Related]
17. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics.
Müller G; Hartz D; Pünter J; Okonomopulos R; Kramer W
Biochim Biophys Acta; 1994 May; 1191(2):267-77. PubMed ID: 8172912
[TBL] [Abstract][Full Text] [Related]
18. [Glimepiride].
Nakamura N
Nihon Rinsho; 2002 Sep; 60 Suppl 9():351-6. PubMed ID: 12387017
[No Abstract] [Full Text] [Related]
19. Mechanism of action of a new class of insulin secretagogues.
Malaisse WJ
Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S140-3. PubMed ID: 10522840
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein inhibition by glibenclamide and related compounds.
Golstein PE; Boom A; van Geffel J; Jacobs P; Masereel B; Beauwens R
Pflugers Arch; 1999 Apr; 437(5):652-60. PubMed ID: 10087141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
